In eosinophilic esophagitis, budesonide orodispersible tablets maintained remission at 48 wk.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 33819066.
- Also identified by DOI 10.7326/ACPJ202104200-044.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Straumann A, Lucendo AJ, Miehlke S, et al. <b>Budesonide orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis.</b> Gastroenterology. 2020;159:1672-85. 32721437.
Medical subject headings
- Budesonide
- Eosinophilic Esophagitis